Cheape Alice C, Murrell Dedee F
a Department of Dermatology , St George Hospital , Sydney , Australia.
b Aberdeen University , Aberdeen , Scotland.
Expert Rev Clin Immunol. 2017 May;13(5):415-423. doi: 10.1080/1744666X.2017.1304820. Epub 2017 Apr 5.
Crisaborole 2% topical ointment is an anti-inflammatory, non-steroidal phosphodiesterase 4 inhibitor which is currently under investigation for its potential role in the treatment of atopic dermatitis and psoriasis. Areas covered: So far, 7 trials have been completed in atopic dermatitis. The 2% strength appeared to be the superior dosing regimen. Pruritus improved significantly within one week. The improvements in objective efficacy assessments in crisaborole-treated patients were also statistically significant compared to the vehicle. Expert commentary: Crisaborole has several key features in its mode of action which distinguish it from existing treatments for atopic dermatitis (AD), notably its activity against the phosphodiesterase E4 (PDE4) pathway, regulating cyclic AMP (cAMP) levels. This is less immunosuppressive than other pathways and has no effect on skin thinning. The pathway interrupts the itch sensation (pruritus) which means that the itch-scratch cycle, the bane in the life of patients with AD, is interrupted, usually as early as a few days into treatment. Hence, with the promising safety profile demonstrated, early treatment of mild to moderate AD patients might help to control AD better and improve quality of life for patients.
2%克立硼罗外用软膏是一种抗炎的非甾体磷酸二酯酶4抑制剂，目前正在研究其在治疗特应性皮炎和银屑病中的潜在作用。涵盖领域：到目前为止，已完成7项关于特应性皮炎的试验。2%的浓度似乎是更优的给药方案。瘙痒在一周内显著改善。与赋形剂相比，克立硼罗治疗患者的客观疗效评估改善也具有统计学意义。专家评论：克立硼罗的作用方式有几个关键特征，使其有别于现有的特应性皮炎（AD）治疗方法，特别是其对磷酸二酯酶E4（PDE4）途径的活性，调节环磷酸腺苷（cAMP）水平。这比其他途径的免疫抑制作用小，且对皮肤变薄无影响。该途径可中断瘙痒感，这意味着瘙痒-搔抓循环（AD患者生活中的祸根）通常在治疗开始几天后就会被中断。因此，鉴于已证明的良好安全性，对轻度至中度AD患者进行早期治疗可能有助于更好地控制AD并改善患者生活质量。
